SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • 1
    Hyjek E, Vardiman JW. Myelodysplastic/myeloproliferative neoplasms. Semin Diagn Pathol 2011; 28: 283297.
  • 2
    Vardiman JW, Bennett J, Bain B, Baumann I, Thiele J. Myelodysplastic/myeloproliferative neoplasm, unclassifiable. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2008. p 8586.
  • 3
    van de Loosdrecht AA, Alhan C, Bene MC, la Porta MG, Drager AM, Feuillard J, Font P, Germing U, Haase D, Homburg CH, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009; 94: 11241134.
  • 4
    Lacronique-Gazaille C, Chaury MP, Le Guyader A, Faucher JL, Bordessoule D, Feuillard J. A simple method for detection of major phenotypic abnormalities in myelodysplastic syndromes: expression of CD56 in CMML. Haematologica 2007; 92: 859860.
  • 5
    Subira D, Font P, Villalon L, Serrano C, Askari E, Gongora E, Castanon S, Gonzalo R, Mata R, Roman A, et al. Immunophenotype in chronic myelomonocytic leukemia: Is it closer to myelodysplastic syndromes or to myeloproliferative disorders? Transl Res 2008; 151: 240245.
  • 6
    Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T. Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells. Leuk Lymphoma 2011; 52: 92100.
  • 7
    Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, la Porta MG, et al. Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012; 26: 17301741.
  • 8
    Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 2008; 112: 26812686.
  • 9
    Van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden V, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008; 111: 10671077.
  • 10
    Kern W, Haferlach C, Schnittger S, Haferlach T. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer 2010; 116: 45494563.
  • 11
    Löffler H, Raststetter J, Haferlach T. Atlas of Clinical Hematology, 6th ed. Heidelberg: Springer; 2004.
  • 12
    Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: A study on 350 cases. Leukemia 2002; 16: 5359.
  • 13
    Gondek LP, Dunbar AJ, Szpurka H, McDevitt MA, Maciejewski JP. SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLoS One 2007; 2: e1225.